Methods for detecting sinusoidal obstructive syndrome (sos)

Abstract

Disclosed are biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of one or more of ST2, ANG2, L-Ficolin, HA, and VCAM1 for prognosing, diagnosing, and/or treating SOS.

What is claimed is: 
     
         1 . A diagnostic biomarker panel comprising suppressor of tumorigenicity 2 (ST2), angiopoietin 2 (ANG2), L-Ficolin, hyaluronic acid (HA) and vascular cell adhesion molecule 1 (VCAM1). 
     
     
         2 . A prognosis biomarker panel comprising L-Ficolin, hyaluronic acid (HA) and vascular cell adhesion molecule 1 (VCAM1). 
     
     
         3 . A method of diagnosing or of aiding diagnosis of sinusoidal obstructive syndrome (SOS) in a subject receiving hematopoietic stem cell transplantation (HSCT), the method comprising:
 measuring in a biological sample from the subject the expression of at least one biomarker selected from the group consisting of ST2, ANG2, L-Ficolin, HA, and VCAM1 by contacting the biological sample obtained from the subject with a specific binding agent that specifically binds to the biomarker, wherein the specific binding agent forms a complex with the biomarker; and   detecting the agent-biomarker complex, thereby determining the biomarker expression level; wherein an elevated biomarker expression level compared to biomarker expression obtained from a biological sample obtained from a control is indicative of SOS.   
     
     
         4 . The method of  claim 3  wherein the biological sample is obtained at day 0 from HSCT. 
     
     
         5 . The method of  claim 3  wherein the biological sample is obtained from day 0 to day 7 from HSCT. 
     
     
         6 . The method of  claim 3  wherein the biological sample is obtained from day 0 to day 14 from HSCT. 
     
     
         7 . The method of  claim 3  wherein the biological sample is obtained from day 0 to day 21 from HSCT. 
     
     
         8 . The method of  claim 3  wherein the specific binding agent is selected from the group consisting of a nucleic acid, an antibody, a receptor, and a lectin. 
     
     
         9 . The method of  claim 3  wherein the biological sample is selected from the group consisting of whole blood and plasma. 
     
     
         10 . The method of  claim 3  wherein detecting the specific binding agent-biomarker complex is selected from the group consisting of microarray analysis, immunoassay, immunohistochemistry, and mass spectrometry. 
     
     
         11 . The method of  claim 3  wherein the measuring comprises contacting the biological sample with a biomarker panel comprising tumorigenicity 2 (ST2), angiopoietin 2 (ANG2), L-Ficolin, hyaluronic acid (HA) and vascular cell adhesion molecule 1 (VCAM1). 
     
     
         12 . A method of prognosing or of aiding prognosis of sinusoidal obstructive syndrome (SOS) in a subject receiving hematopoietic stem cell transplantation (HSCT), the method comprising:
 measuring in a biological sample from the subject the expression of at least one biomarker selected from the group consisting of ST2, ANG2, L-Ficolin, HA, and VCAM1 by contacting the biological sample obtained from the subject with a specific binding agent that specifically binds to the biomarker, wherein the specific binding agent forms a complex with the biomarker; and   detecting the agent-biomarker complex, thereby determining the biomarker expression level; wherein an elevated biomarker expression level compared to biomarker expression obtained from a biological sample obtained from a control is indicative of a prognosis for a subject having SOS.   
     
     
         13 . The method of  claim 12  wherein the biological sample is obtained at day 0 from HSCT. 
     
     
         14 . The method of  claim 12  wherein the biological sample is obtained from day 0 to day 7 from HSCT. 
     
     
         15 . The method of  claim 12  wherein the biological sample is obtained from day 0 to day 14 from HSCT. 
     
     
         16 . The method of  claim 12  wherein the biological sample is obtained from day 0 to day 21 from HSCT. 
     
     
         17 . The method of  claim 12  wherein the specific binding agent is selected from the group consisting of a nucleic acid, an antibody, a receptor, and a lectin. 
     
     
         18 . The method of  claim 12  wherein the biological sample is selected from the group consisting of whole blood, plasma and serum. 
     
     
         19 . The method of  claim 12  wherein detecting the specific binding agent-biomarker complex is selected from the group consisting of microarray analysis, immunoassay, immunohistochemistry, and mass spectrometry. 
     
     
         20 . The method of  claim 12  wherein the measuring comprises contacting the biological sample with a biomarker panel comprising L-Ficolin, hyaluronic acid (HA) and vascular cell adhesion molecule 1 (VCAM1).